Evidence map›Paper›PMID 41184753›Full record

ArticleBMC infectious diseases2025

Understanding causes of incomplete reports of adverse drug reactions associated with dolutegravir-based HIV treatment in uganda: a qualitative study.

Henry Zakumumpa, Helen Byomire Ndagije, Joanitah Atuhaire, Julius Mayengo, Francis Odipiyo, Kiguba Ronald

Abstract read
In one paragraph

Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Henry ZakumumpaCollege of Health Sciences, Makerere University, Kampala, Uganda. hzakumumpa@cartafica.org.
Helen Byomire NdagijeNational Pharmacovigilance Centre, National Drug Authority, Kampala, Uganda.
Joanitah AtuhaireNational Pharmacovigilance Centre, National Drug Authority, Kampala, Uganda.
Julius MayengoNational Pharmacovigilance Centre, National Drug Authority, Kampala, Uganda.
Francis OdipiyoNational Pharmacovigilance Centre, National Drug Authority, Kampala, Uganda.
Kiguba RonaldCollege of Health Sciences, Makerere University, Kampala, Uganda.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAlthough dolutegravir (DTG)-based HIV treatment has demonstrated superior efficacy, it has been associated with adverse drug reactions (ADRs). Robust pharmacovigilance systems that ensure that received ADRs reports are complete and accurate facilitate timely regulatory decision making. However, there is little research seeking to understand the contexts underpinning data capture of DTG- associated ADRs. We sought to understand barriers to achieving completeness of DTG-associated ADR reports in HIV clinics in Uganda.

methodsWe adopted a qualitative exploratory research design. Between August and October 2024, we conducted 36 in-depth interviews with HIV clinicians and eight focus groups with people with HIV or PWH (56 participants) in the HIV clinics of 12 purposively selected health facilities across Uganda. Data were analyzed by thematic approach.

resultsOur study unearthed patient-based barriers to achieving completeness of data in ADR reports which include the six-monthly appointment spacing intervals for PWH which impede recall of events surrounding ADRs, difficulty by PWH in eliciting details on DTG medication (such as brand and batch numbers), non-disclosure of concurrent use of herbal medicines and the fear by PWH of being switched away from DTG-based therapy which was perceived as superior. Health workforce barriers include a novel finding of 'professional agency' whereby HIV clinicians manage DTG-associated ADRs at an individual-level, fear of inviting scrutiny post-reporting impedes the supply of complete details on ADR reports such as on dosage as well as the low awareness among mid-cadres such as nurses of the importance of providing complete ADR reports in enabling regulatory action. Health system barriers include the reported shortage of in-puts for conducting laboratory investigations of suspected ADRs and limited incentives to reporters for providing complete information on ADR reports.

conclusionHealth workers perceived factors underpinning incomplete DTG-associated ADR reports in Uganda as stemming from patient-based factors (e.g. non-disclosure of concomitant use of herbal medicines), health workforce-drivers (e.g. 'professional agency' in responding to ADRs) and health system constraints (lack of incentives for reporting). The policy and programming implications for improving data quality in reporting DTG-associated ADRs in Uganda and countries with similar setting are discussed.

Indexed as

Adverse Drug Reaction Reporting SystemsAnti-HIV AgentsDrug-Related Side Effects and Adverse ReactionsHeterocyclic Compounds, 3-RingHIV InfectionsOxazinesPiperazinesPyridonesAdultDolutegravirFemaleFocus GroupsHumansMaleMiddle AgedPharmacovigilanceAnti-HIV AgentsDolutegravirHeterocyclic Compounds, 3-RingOxazinesPiperazinesPyridonesAdverse drug reactionsAdverse eventsDolutegravirHIV treatmentPharmacovigilanceSide effects

Identifiers

PMID41184753
PMCPMC12581420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.